Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Memphasys Ltd ( (AU:MEM) ) has shared an announcement.
Memphasys Limited has announced a change in its company secretary, with Mr. Andrew Metcalfe concluding his role and Mr. Stefan Ross stepping in as the new Company Secretary effective 8 October 2025. Mr. Ross brings over 17 years of experience in governance and compliance, which will be instrumental as Memphasys progresses the commercialisation of its Felix™ System, aiming to establish it as a global standard in sperm selection.
More about Memphasys Ltd
Memphasys Limited (ASX: MEM) is focused on the commercialisation of its patented Felix™ System, a novel bioseparation technology for assisted reproduction. Felix™ combines electrophoresis with proprietary size-exclusion membranes to rapidly isolate the most viable sperm cells for use in human fertility treatments. The company’s strategy is centred on securing contracted sales, driving adoption through key clinical and distribution partnerships, and scaling production capacity. With regulatory and commercial pathways advancing, Memphasys is positioned to deliver on its vision of establishing Felix™ as a new global standard in sperm selection.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.46M
See more insights into MEM stock on TipRanks’ Stock Analysis page.